ANNUAL REPORT 2012 - TiGenix

The following paragraphs contain brief
industries through different stages of growth.
biographies of each of the directors or in case Before commencing his MBA, he worked three
of legal entities being director, their permanent years as a research engineer in environmental
representatives, with an indication of other biotechnology. Since June 2012, Mr. Beyen is
mandates as member of administrative, Chairman of the Supervisory Board at Erytech
management or supervisory bodies in other Pharma SA, a French biopharmaceuticals
companies during the previous five years company. He also is a manager of Axxis
(with the exception of the subsidiaries of the V&C BVBA, as well as member of the board
Company) :
of BIO.be, and commissioner for the Flemish
government on the board of the Flemish
Jean Stéphenne, permanent representative Institute of Biotechnology (VIB).
of Innosté SA : Chairman and Independent
Director
Eduardo Bravo : CEO and Managing Director
(executive)
Jean Stéphenne was until April 2012 Member
of the Corporate Executive Team of
Mr. Eduardo Bravo has more than 20 years
GlaxoSmithKline (GSK), and Chairman and experience in the pharmaceutical industry.
President of GSK Biologicals in Wavre, Belgium, He held several senior management positions
which he built into a world leader in vaccines. at Sanofi-Aventis, including Vice President for
He currently serves as Chairman of BESIX, Latin America, a division with 2000 employees
IBA, Vesalius Biocapital, Nanocyl, Bepharbel, and sales of more than EUR 1 billion. At
BioWin and Welbio, and as Board member of Sanofi-Aventis he also held senior positions in
BNP Paribas Fortis, VBO/FEB, Groupe Bruxelles Marketing and Sales for Europe and he was
Lambert (GBL), Helse, Uteron and OncoDNA. General Manager for Belgium. Prior to his
He used to serve as Board member of Auguria tenure at Sanofi-Aventis, Mr. Bravo spent 7 years
Residential Real Estate Fund, which is currently at SmithKline Beecham in sales positions both
in liquidation.
nationally and internationally. Mr. Bravo holds a
degree in Business Administration and an MBA
Gil Beyen, permanent representative of Gil (INSEAD), and is co-Chair of the Alliance of
Beyen BVBA : CBO and Managing Director Advanced Therapies.
(executive)
Willy Duron : Independent Director
Mr. Gil Beyen gained an MSc in bioengineering
from the Katholieke Universiteit Leuven
Mr. Willy Duron has been an independent
(Belgium) in 1984 and obtained an MBA from board member of TiGenix since February
the University of Chicago (U.S.) in 1990. He 2007. He was the Company’s Chairman
founded the Company in 2000 and served as from September 2007 to September 2012. He
Chief Executive Officer of the Company until started his career at ABB Verzekeringen in
2011. Before founding TiGenix, Mr. Beyen worked 1970, becoming a member of the executive
as a management consultant at Arthur D. Little committee in 1984. Mr. Duron holds a MSc
(ADL) in Brussels, where he was responsible for degree in mathematics from the University of
their healthcare and biotechnology practice. Gent and a MSc degree in actuarial sciences
In this function, he assisted a broad range of from the Katholieke Universiteit Leuven. He
companies in the biomedical and biotech currently is a member of the board of directors
86 TiGenix I annual report 2012